Research on hormonal treatments of prostate cancer over the past 20 y have focused on maximizing androgen ablation through combination therapy. Maximal androgen ablation increases treatment-related side-effects and expense and fails to prolong time to androgen-independent (AI) progression. The rationale behind intermittent androgen suppression (IAS) is based on: (1) observations that androgen ablation is palliative, not curative in most patients where quality of life must be considered; (2) assumption that immediate androgen ablation is superior to delayed therapy in improving survival of patients with prostate cancer; and (3) the hypothesis that if tumor cells which survive androgen withdrawal are forced into a normal pathway of differentiation by androgen replacement, then apoptotic potential might be restored and progression to androgen independence may be delayed. Observations from animal model studies suggest that progression to androgen-independence involves adaptive responses to androgen deprivation which are, in turn, modulated by intermittent androgen replacement.
Rationale for intermittent androgen suppression
Approximately 80% of prostate cancer patients achieve symptomatic and objective responses following androgen suppression and serum prostate speci®c antigen (PSA) levels decrease in almost all patients. Surgical or medical castration results in a median progression-free survival of 12 ± 33 months and a median overall survival of 23 ± 37 months in patients with stage D 2 disease.
1,2 However, for reasons that remain unde®ned, the apoptotic process induced by androgen ablation fails to eliminate the entire malignant cell population. 3 Another limitation of conventional androgen ablation is that it accelerates the rate of progression of prostate cancer to an androgenindependent state, 3 and after a variable period of time averaging 24 months, progression inevitably occurs with increasing serum PSA levels and androgen-independent growth. Over the past two decades, most efforts have focused on maximizing the degree of androgen suppression therapy by combining agents that inhibit or block both testicular and adrenal androgens. Unfortunately, large randomized studies and meta-analyses have concluded that maximal androgen ablation increases treatment-related side-effects and expense and has not been shown to prolong time to androgen-independent progression in most patients. 2, 4, 5 The idea of inducing more than one regression of androgen-dependent malignancy arose from the observation that the involution of prostate brought on by castration is an active process involving the rapid elimination of a large number of epithelial cells. 6, 7 It was ®rst postulated that the replacement of androgens even in small amounts would have a conditioning effect on surviving cells allowing them to conserve or regain desirable traits of differentiation. 7 In the case of tumors, several lines of evidence obtained by Foulds 8 and Noble 9 implied that long periods of hormone deprivation simply accelerated progression towards autonomous growth and thus were better avoided. Although no practical method of countering progression by hormonal means emerged from this work, the subsequent demonstration that consecutive episodes of testosterone-induced regeneration of involuted prostate completely restored the susceptibility of the epithelium to further androgen withdrawal, 10 was an incentive to try similar experiments on tumors. The potential bene®ts of intermittent, rather than continuous therapy, include improved quality of life through reduced therapy-induced side effects, decreased costs, and possibly improved control over progression to androgen-independence. However, intermittent androgen suppression (IAS) is a feasible treatment option only if immediate hormone therapy is superior to delayed, and if adaptive mechanisms help mediate androgen-independent progression.
Balancing the bene®ts of immediate androgen ablation
If time to disease progression and overall survival is similar with immediate (that is at the time of diagnosis of metastatic or recurrent disease) or delayed (namely waiting for the development of symptoms) androgen ablation, then the role and rationale for IAS would be limited. Measuring serum PSA after radical prostatectomy or radiotherapy would be a waste of time and resources, and only patients with clinical symptomatic recurrences would require hormonal therapy. Accumulating evidence, however, suggests that treatment should commence at the time of diagnosis of locally advanced or metastatic disease (Table 1) . Although the ®rst VACURG study 11 found delayed endocrine therapy equivalent to immediate endocrine therapy, re-analysis by Byar 12 and evidence from animal models of prostate cancer indicate that early androgen ablation is more effective.
3,13 The Goldie ± Coldman 14 hypothesis of increasing somatic genomic alterations and tumor heterogeneity over time provides additional theoretical evidence supporting initiation of therapy as early as possible. Most notably, the MRC study from the UK randomised over 800 men with advanced M 0 or M 1 disease to immediate vs deferred therapy and showed that palliative surgery for bladder outlet or ureteral obstruction was reduced by close to 50% and disease-speci®c survival improved with immediate therapy. 15 Another, more recent study from the EORTC also demonstrated signi®cant improvement in time to disease progression, and 5 y survival (58 vs 78%) in patients with locally advanced disease treated with radiotherapy and either immediate androgen ablation for 3 y or delayed therapy until symptomatic progression. 16 Coincident with accumulating evidence supporting immediate therapy is a shift in the target population receiving androgen ablation from metastatic disease to PSA failures after radical prostatectomy or radiotherapy. Use of PSA for early detection has produced a stage migration and 50% decrease in the incidence of stage D2 disease over the last two years. 17 Because the median survival in D2 disease is only 2 ± 3 y, the long term sideeffects of androgen ablation do not become apparent and are therefore not clinically relevant. However, use of PSA and stage migration have resulted in earlier diagnosis at younger ages and earlier stages of disease, with the prospect of much longer therapy and risk of chronic complications. Furthermore, use of PSA to detect biochemical recurrences following radical prostatectomy or radiotherapy identi®es men destined to recur who may bene®t from early adjuvant therapy 13 ± 16 but who have life expectancies exceeding 10 y. Hence, combinations of stage migration, earlier diagnosis of PSA recurrences, longer life expectancies, and trend towards immediate therapy will force clinicians to balance the potential bene®ts of early adjuvant therapy with risks of development of metabolic complications, as well as the increased expense, associated with long-term continuous androgen withdrawal therapy. These metabolic complications include loss of bone mass (osteoporosis) and fractures, loss of muscle mass and anemia with easy fatigue and decreased energy levels, changes in lipid pro®le with increased risk of cardiovascular complications, glucose intolerance, and depressive and/or irritable personality changes. 18 IAS offers clinicians an opportunity to improve quality of life in patients with prostate cancer by balancing the bene®ts of immediate androgen ablation (delayed progression and prolonged survival) while reducing treatment-related side effects and expense.
Modulating adaptive responses mediating androgen independence
Prostatic carcinoma is an androgen-dependent tumor, manifested by apoptosis, cell cycle arrest, and changes in androgen-regulated gene expression after androgen ablation. 19, 20 Unfortunately, progression to androgenindependence nearly always occurs in prostate cancer cells after androgen ablation. Cellular and molecular mechanisms that help mediate progression to androgenindependence include expansion of pre-existing clones of androgen-independent cells (clonal selection), 21, 22 up-regulation of androgen-repressed adaptive mechanisms capable of aborting the apoptotic process (adaptation), 3, 23 androgen-receptor mutations leading to a constitutively active transitional factor, 24 or production of factors capable of interacting with the androgen-receptor (protein± protein interactions). 25 A complete review of these mechanisms is beyond the scope of this review, but likely all variably operate in heterogenous tumors like prostate cancer. Clonal expansion of AI cells after castration cannot be prevented by current therapeutic strategies because of resistance to traditional cytotoxic chemotherapies. However, it may be possible to inhibit or modulate the adaptive changes in gene expression precipitated by androgen ablation through the differentiating in¯uence of androgen.
The ability of benign or malignant prostate cells to undergo apoptosis and express PSA are acquired as a feature of differentiation of prostatic cells under the in¯uence of androgens. Even in malignancy, the ability to undergo apoptosis is acquired as a feature of differentiation under the in¯uence of androgens. Therefore in the absence of androgens, it is impossible for dividing cells to differentiate and become pre-apoptotic again, which explains why recurrent tumor growth after castration is characterized by androgen independence. 3, 19 The rationale behind IAS is based on the hypothesis that if tumor cells surviving androgen withdrawal are forced along a normal pathway of differentiation by androgen replacement, then apoptotic potential might be restored and progression to androgen independence delayed. It follows that if androgens are replaced soon after regression of tumor, it should be possible to bring about repeated cycles of androgen-stimulated growth, differentiation and androgen-withdrawal regression of tumor.
Preclinical studies of intermittent androgen suppression
Dunning R3327 rat prostatic adenocarcinoma Using the Dunning rat carcinoma as a model of progression to androgen-independence, Isaacs et al 21, 22 emphasized the importance of genetic instability, which increases tumor heterogeneity by increasing the number of distinctly different clones of cells, analogous to the Goldie ± Coldman hypothesis of tumor progression.
14 Androgen-independent progression results from selective outgrowth of one or more androgen resistant clones after androgen ablation. Treatment of the Dunning R3327 carcinoma by cyclic therapy was studied by Trachtenberg et al 26 but no signi®cant growth reduction with the IAS group was observed and they concluded that IAS was inferior to early castration in inhibiting tumor growth. Similarly, Russo et al 27 reported that Dunning R3327 tumors treated with continuous or intermittent DES had tumor volumes at death smaller than control or castrate rats, but a survival advantage was achieved only in the castrate or continuous DES groups. Although the intermittent regimen was successful in checking tumor volume, it did not yield a survival advantage and in this respect was inferior to castration. The foregoing experiments on the Dunning R3327 prostatic adenocarcinoma draw attention to importance of using cyclic androgen deprivation only for the treatment of androgendependent cancer. Dunning tumors are androgen-sensitive, not androgen-dependent, and apoptosis with tumor regression does not occur following castration. The failure to improve outcome with IAS in Dunning tumors is not an unexpected result. Indeed, IAS may be detrimental because of stimulation of androgen-sensitive cells when testosterone levels increase. Androgen ablation with the addition of cytotoxic agents appears to be the most effective therapy in this model.
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Shionogi mouse carcinoma IAS of the androgen-dependent Shionogi carcinoma has been carried out experimentally by transplanting the tumor into a succession of male mice. The cycle of transplantation and castration-induced apoptosis was successfully repeated four times before growth became androgen-independent during the ®fth cycle. 28 The mean time to androgen independence increased 3-fold compared to one-time castration, consistent with a retarding effect of cyclic therapy on tumor progressions. Some caution is required in the interpretation of these results since the procedure of transplanting a regressing tumor from a castrated to a non-castrated animal temporarily may reduce the rate of cell division and give rise to an apparent delay in progression. However, in addition to tumor growth, other markers of androgen dependence in this model, castration-induced apoptosis and TRPM-2 gene expression, are maintained three times longer with IAS compared to continuous therapy, paralleling and supporting the changes in tumor volume.
LNCaP prostate tumor model
As in human prostate cancer, serum PSA levels in this model are androgen-regulated and proportional to tumor volume. 29 ± 32 After castration, serum and tumor-cell PSA levels decrease by 80% and remain suppressed for 3 ± 4 weeks before increasing again. With intermittent testosterone withdrawal and replacement in castrated mice bearing LNCaP tumors, androgen-independent regulation of the PSA gene was delayed 3-fold. 33 Thalmann et al 34 reported evidence which suggests that continuous androgen suppression may facilitate development of androgen-independent osseous metastasis. Characterization of androgen-independent-LNCaP cell lines produced a subline (C4 ± 2) that metastasized to bone, and interestingly, the incidence of osseous metastases appeared higher in castrated than in intact male hosts. Finally, two separate groups of investigators 35, 36 independently reported isolating androgen-repressed LNCaP cell lines that grew faster in castrated than in intact hosts, and with growth rates that were actually inhibited by androgens.
Taken together, these data emphasize the potentially diverse biologic effects that androgens have on a heterogenous and adapting tumor population and supports the concept that progression to androgen-independence involves loss of androgen-induced differentiation and/ or upregulation of androgen-repressed growth regulatory pathways.
Clinical studies of intermittent androgen suppression
Reports of multiple regressions of hormone dependent malignancy are rare in the clinical and scienti®c literature. Stoll 37 drew attention to the balance between inhibition and stimulation of the growth of breast cancer in an elderly woman who was treated intermittently with estrogen. Regression of tumor occurred three times over a period of ®ve years, after which an estrogen withdrawal response resulted in a forth remission. Bruchovsky described sequential responses of a pulmonary metastases of breast cancer in a female patient whose endocrine therapy consisted of radiation ovariectomy, administration of androgen, discontinuation of androgen and adrenalectomy respectively. 19 Regressions followed each procedure and the tumor size was successfully held in check.
The intermittent regulation of serum testosterone levels for therapeutic purposes in prostate cancer was ®rst attempted with cyclic administration of estrogenic hormone. 38 Nineteen patients with advanced prostate cancer received diethylstilbestrol until a clinical response was clearly demonstrated and then it was withheld until symptoms recurred. One additional patient was treated with¯utamide using a similar schedule. The mean duration of initial therapy was 30 months (range 2±70 months). Subjective improvement was noted in all patients during the ®rst three months of treatment. When therapy was stopped, 12 of the 20 patients relapsed after a mean interval of eight months (range 1±24 months) and all subsequently responded to re-administration of drug. Therapy-induced impotency was reversed in 9 of the 10 men within three months of the break in treatment. An improved quality of life was achieved owing to the reduced intake of diethylstilbestrol, and no adverse effects on survival were apparent.
The ®rst nonsteroidal antiandrogens became available around the same time as this study, and most clinical research focused on the combined use of LHRH agonists and antiandrogens. 2, 4 Little attention has been given to the reversibility of action of LHRH agonists, the signi®-cance of which is far-reaching. The potential for a full recovery from therapy makes it possible to alternate a patient between periods of treatment and no-treatment. Furthermore, serial serum PSA measurements, which were not available at the time of the study by Klotz et al, 38 permit accurate monitoring of disease activity and serve as trigger points for stopping and restarting therapy. In response to this androgenic stimulus, atrophic cells are recruited into a normal pathway of differentiation where the risk of progression to androgen-independence is reduced. With the associated movement through the division cycle, the cells become pre-apoptotic again making it possible to repeat therapy.
Preliminary results of IAS in 47 patients using reversible medical castration and serum PSA as trigger points were reported by Goldenberg et al 39 in 1995, and updated to include 60 patients by Gleave et al 40 in 1997. Seventy patients with a minimum follow-up of 12 months (mean 46 mo.) have now been accrued, 41 with clinically localized and 29 with metastatic disease. Mean initial serum PSA was 110 mg/L. Treatment was initiated with combined androgen blockade and continued for an average of nine months. Because prognosis is poor in patients who do not achieve normal PSA levels after androgen ablation, only patients with PSA nadir levels below 4 mg/L are eligible for the IAS protocol. Medication was then withheld until serum PSA increased to mean values between 10±20 mg/L. This cycle of treatment and no-treatment was repeated until the regulation of PSA became androgen independent (Figure 1) .
Thirty-two men are currently in their second cycle and 24 are in their third or higher cycle. The mean time to PSA nadir during the ®rst three cycles was ®ve months. The ®rst two cycles averaged 18 months in length with 45% of the time off therapy, while the third cycle averaged 15.5 months. Serum testosterone returned to the normal range within a mean of eight weeks of stopping treatment. The off-treatment period in all cycles was associated with an improvement in sense of well-being, and the recovery of libido and potency in the men who reported normal or near-normal sexual function before the start of therapy. Androgen-independent progression occurred in 10 out of 29 stage D patients and 7 out of 41 with localized disease after a mean followup of 43 months. Of 21 stage D2 patients, 12 remain on study with stable disease. Nine patients have died, three from non-cancer related illness, with median time to progression and overall survival of 26 and 42 months, respectively.
Since these initial reports, other investigators have con®rmed the feasibility of IAS in patients with advanced or recurrent prostate cancer (Table 2 ). Higano et al 41 reported their experience in Seattle using IAS with a cohort of 22 patients (7 stage D2, 3 stage D1, 2 stage T2-3, and 10 biochemical failures after de®nitive local therapy). The median follow-up was 26 months, and all patients remain alive with two patients (1 biochemical relapse and 1 D1) progressing to androgen-independence at 33 and 22 months, respectively. Time off therapy for stage D2 patients was 35%, slightly less than the percentage of time off for biochemical relapsers (44%). All patients who were cycled off therapy for three or more months noted some improvement in overall quality of life.
Oliver et al 42 in London reviewed 20 patients with localized or metastatic prostate cancer who elected to stop androgen ablation therapy after median of 12 months (range 3±48). After a median of nine months off therapy, 13 patients progressed and were restarted on androgen ablation, and 10 of these remain progression-free after two years. Of particular interest were seven patients who were on therapy for 3, 3, 3, 16, 12, 5, and 12 months and subsequently off hormone therapy for 33, 43, 36, 36, 36, 40 , and 42 months, respectively. These authors commented on trends in their small series for better duration off therapy in older patients and in those with nonmetastatic disease.
Intermittent androgen suppression for prostate cancer M Gleave et al
Carrol et al 43 in San Francisco reported on their initial experience with 47 patients with clinically localized prostate cancer treated with an IAS protocol. Patients were followed for a mean of 24 months and completed on average two treatment cycles. Only one patient failed to respond to reinstitution of treatment, and no other patients demonstrated progression during the followup period, illustrating the ability of reversible medical castration to induce repeated cycles of therapeutic response. Average cycle length was 16 months for the ®rst cycle and 11 months for the second. Patients averaged 50% of their time off therapy.
A prospective phase II study in post-radiotherapy recurrences has been initiated at 4 centers across Canada and over 100 patients have now been accrued. 44 Patients are treated for nine months and cycled off therapy until serum PSA rises back to levels between 8 and 15 mg/L (Figure 2) . Endpoints of the study include monitoring length of time off therapy, quality of life measurements, and time to androgen-independent progression. First cycle analysis demonstrated improve quality of life measurements when men were cycled off therapy.
Observations from these series add to and are consistent with the initial reports from Vancouver 39, 40 in terms of response rates and time off therapy. Each of these small series illustrate that relatively short on-therapy periods may result in off-therapy intervals of several years, which suggests that continuous androgen ablation may represent over-treatment in a signi®cant proportion of men. These IAS series use serum PSA as the marker of response to therapy and tumor progression, as well as a guide for when to restart therapy. Serum PSA increases before evidence of tumor progression becomes apparent in more than 90% of patients with progressive disease treated with continuous therapy. 1, 47 As a result, bone scans for monitoring disease progression are used only in patients with new symptoms or biochemical progression. Dissociation between biochemical and tumor progression occasionally occurs, however, and stopping therapy with IAS in this scenario would likely accelerate tumor progression. Although unusual, dissociation between biochemical and clinical progression emphasizes the need for Phase III controlled data to better characterize the risks and bene®ts of IAS.
Candidates for intermittent androgen suppression
Failure of serum PSA to nadir below 4 mg/L after six months of therapy is associated with a short duration of Figure 1 Androgen ablation results in apoptosis and upregulation of previously androgen-repressed genes (for example Bcl-2, TRPM-2). However, not all cells are eliminated and in the absence of androgens, proliferating cells do not differentiate to become preapoptotic again, which results in development of the androgen-independent phenotype. With intermittent re-exposure to testosterone (T ), proliferating cells differentiate and become preapoptotic again, permitting another round of androgen ablation-induced apoptosis and tumor regression (T 7 ). Inserts are northern analyses illustrate constitutive overexpression of PSA gene expression, a marker of androgen-independence in LNCaP tumors, is delayed by intermittent compared to continuous androgen suppression in LNCaP tumours. 33 Intermittent androgen suppression for prostate cancer M Gleave et al response to androgen ablation and poor prognosis, 47 and IAS is not offered to these patients. Men with T x N 1±3 M 0 or T x N x M 1 who are sexually active, compliant to close followup, or who do not tolerate the side effects of androgen ablation can be considered for IAS as long as they realize it is investigational. Biochemical failures after radiotherapy or surgery are groups most likely to bene®t from IAS, which permits¯exibility in applying and achieving survival bene®ts of immediate therapy, 12±16 while balancing potential longterm side effects and costs of continuous therapy. 18 
Length of treatment cycle
Conceptually, androgen ablation should be continued until maximal castration-induced apoptosis and tumor regression have been induced, but stopped before constitutive development of the androgen-independent phenotype. Premature termination of therapy would permit some cancer cells destined to undergo apoptosis to survive upon reexposure to testosterone. Some investigators 43 treated for 1±2 months past PSA nadir, which results in Figure 2 Composite results on 70 patients with prostate cancer treated with intermittent androgen suppression, of whom 14 are in their ®rst cycle of treatment, 32 in their second cycle, and 13 in their third, 5 in their fourth cycle, and 6 in their ®fth cycle. Mean serum PSA at the start of the ®rst, second, third and fourth cycles was 110 mg/L, 16 mg/L, 12, and 14 mg/L, respectively. The ®rst three cycles averaged 18, 18, and 15.5 months in length, respectively.
Figure 3
Schema of intermittent androgen suppression therapy for patients with biochemical recurrences following radiation therapy for clinically localized prostate cancer. 41 
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local met n/a n/a n/a n/a n/a n/a n/a Carrol shorter`on' cycles and shorter`off' cycles, but similar percentages of time spent`off' therapy. The de®nition of nadir must be consistent, however, and should be the lowest, plateau serum PSA level attained following institution of androgen ablation. For comparison of future series, standardization of treatment regimens are necessary. We have used a nine month treatment`on' cycle for the following reasons. Firstly, PSA nadir and maximal soft tissue regression is not reached until 8 or 9 months in many patients. 39, 40 Similarly, the duration of time necessary for PSA to reach its nadir in a group of patients with clinically con®ned disease after institution of neoadjuvant hormone therapy is often longer than six months. 45, 46 Using a lower limit of sensitivity of 0.2 mg/L, PSA nadir was reached in only 34% after three months, 60% after ®ve months, 70% after six months, and 84% at eight months. The initial rapid decrease in PSA results from cessation of androgen-regulated PSA synthesis and apoptosis, while the ongoing slower decline re¯ects decreasing tumor volume. Secondly, immunostaining for proliferation markers (Ki-67 and PCNA) showed minimal or reduced activity in radical prostatectomy specimens after eight months of neoadjuvant therapy compared to pretreatment biopsy specimens. 45, 48 Thirdly, levels of the antiapoptotic oncoprotein, Bcl-2, increase beginning during the ®rst three months of NHT, 49 and remain elevated after eight months of therapy, 48 consistent with its role in prevention of castration-induced apoptosis. 50 These observations suggest that Bcl-2 is upregulated early after castration and that concerns regarding constitutively increased levels developing between six and nine months of therapy must be balanced by bene®ts of ongoing tumor involution during this period of time. Interestingly, preliminary experiments using RT-PCR revealed that androgen downregulates Bcl-2 expression in LNCaP cells in vitro, 51 an observation which may be signi®cant when considering mechanisms by which IAS may delay time to AI progression. Based on time to PSA nadir, reduced prolifation marker staining, and early upregulation of Bcl-2, we treat patients for nine months prior to stopping therapy.
When to restart
Trigger points for reinstitution of androgen withdrawal therapy are similar among investigators reporting on their IAS experience. 39±44 Although the optimal time remains unde®ned and empirical, time off therapy should be long enough to permit normalization of improved quality of life and testosterone-induced tumor cell differentiation. Re-exposure of tumor cells to testosterone during the off-treatment cycles of IAS is critical to the underlying hypothesis and rationale behind IAS. Furthermore, recovery of testosterone between treatment cycles is necessary for recovery of sexual function, reduced side effects, and normal sense of well-being. Until more information is obtained, PSA trigger points are regarded as tentative settings only. Trigger points are individualized and factors that are considered include pretreatment PSA levels, stage, PSA velocity, presence of symptoms, and tolerance of androgen ablation therapy. In general, in patients with metastatic disease and high pretreatment PSA levels, therapy is restarted when PSA increases to 20 mg/L; in patients with locally recurrent disease and moderately elevated pretreatment PSA levels, therapy is restarted when PSA reaches 6 ±15 mg/L, and earlier for post-radical prostatectomy recurrences.
Future directions
Observations from accumulating experience in Phase II studies suggest that IAS does not have a negative impact on time to progression or survival, both of which appear similar to continuous combined therapy. However, the available information about IAS remains limited and leaves several questions unanswered. The issue of survival is the most important and phase III randomized studies are required to accurately assess the effects of IAS on this critical parameter. IAS appears to improve quality of life by permitting recovery of libido and potency, increasing energy levels and enhancing sense of well-being during off-treatment periods. The animal and preliminary clinical studies have helped identify groups of patients who are most likely to bene®t from IAS, to determine optimal duration of treatment, and to suggest trigger points on when to re-start therapy again. The therapeutic strategy and trigger points in each situation are guided by serum PSA. It is important to look for other signs of progressive disease when serum PSA is used to monitor disease activity, in case of the unusual scenario of PSA-negative disease progression.
The possibility of expanding the use of IAS to earlier stage disease should be examined in greater detail. Conceivably, IAS might become an alternative to radical prostatectomy or irradiation for the primary treatment of localized prostate cancer in some men with life expectancies of less than 15 y. The prospect of improving the results of IAS by increasing the length and number of cycles is attractive. Prolongation of the length of each`off' treatment cycle may be possible with 5a-reductase inhibitors like ®nasteride. Augmentation of intermittent therapy might be accomplished by the administration of apoptotic-enhancing agents (for example antisense Bcl-2 strategies), differentiating agents, or gene therapies at speci®c times during a cycle of treatment when the modality-of-choice would have its maximum effect.
